HOME >> BIOLOGY >> NEWS
Wellcome Trust and GlaxoSmithKline announce partnership to target drug-resistant hospital infections

The Wellcome Trust and GlaxoSmithKline (GSK) today announced a collaboration to develop a new class of antibacterials to combat the rise of certain drug-resistant hospital-acquired infections, including those that lead to pneumonia. The collaboration is part of the Wellcome Trusts Seeding Drug Discovery initiative, aimed at tackling unmet medical needs.

GSK has received a 4 million award from the Trust to accelerate development of compounds for the treatment of Gram-negative bacteria which are becoming increasingly resistant to multiple antibacterials. GSK will make a matching contribution in staff, equipment, and other programme costs. The Trust will receive a financial consideration on any commercial product resulting from the collaboration.

"Our ability to tackle drug-resistant infections is reaching crisis level with few new antimicrobial agents on the horizon," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "Antibacterials are expensive to develop and may be held in reserve, limiting their market potential. It can be difficult, therefore, for companies to recoup their outlay in R&D costs.

This is where the Wellcome Trust believes it can make a difference through partnership. GSK has demonstrated a continuing commitment to discover and develop new antibacterials, aimed at addressing the growing threat of resistance. Our partnership will further support its research programmes."

The research will target Gram-negative bacteria, such as Pseudomonas, Klebsiella and Acinetobacter, which are increasingly resistant to available antibacterials and commonly cause hospital-acquired pneumonia and septic shock, particularly in patients in intensive care units. Without adequate therapy, patients often confront a poor prognosis mortality is high, and recovery, when it occurs, can be long and complicated.

Dr Patrick Vallance, Senior Vice President of Drug Discovery at GSK, commented: Infectio
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
29-Apr-2007


Page: 1 2

Related biology news :

1. Burroughs Wellcome Fund awards $14M to support physician-scientists
2. Burroughs Wellcome fund awards $8.25 million in grants to physician-scientists
3. Major Wellcome Trust award to take science from the bench to the bedside
4. A Wellcome brain gain for world leading neuroscience lab
5. Burroughs Wellcome Fund to support Project Suc-SEED at CIIT Centers for Health Research
6. BioMed Central applauds Wellcomes leadership on Open Access
7. Yale scientist studying virus infections named Burroughs Wellcome Investigator
8. Wilson Center and Pew Charitable Trusts expand efforts to examine risks/benefits of nanotechnology
9. Trusting your instincts leads you to the right answer
10. Leeds Teaching Hospitals NHS Trust to host press conference call/webcast on data published in NEJM
11. GlaxoSmithKlines rotavirus vaccine candidate shown effective

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... July 01, 2020 , ... ... completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the ... clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers ...
(Date:6/28/2020)... ... 2020 , ... In an upcoming episode scheduled for the fall of 2020, ... solutions (POCT). Check local listings for more info. , Today, the majority of testing ... to labs throughout the country. Results are then available several days later. Now, in ...
(Date:6/23/2020)... ... 23, 2020 , ... First Aid Africa, a Scottish charity ... and manufacturer of innovative portable renewable energy equipment, have announced the success of ... COVID-19 pandemic in Zambia. , One of Renovagen’s FAST FOLD portable solar power ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in ... the patient's condition, treatment may be offered IV, intrathecal or with a combination. , ... dementia, and the incidence continues to increase as individuals live longer. There is no ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the COVID-19 pandemic ... drug treatment. In an effort to better understand the cellular responses to COVID-19, ... imaging dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules ...
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
Breaking Biology Technology:
Cached News: